Total Payments
$320,677
2024 Payments
$192,490
Companies
25
Transactions
339
Medicare Patients
1,231
Medicare Billing
$175,873
Payment Breakdown by Category
Other$202,924 (63.3%)
Research$74,182 (23.1%)
Consulting$18,843 (5.9%)
Travel$15,457 (4.8%)
Food & Beverage$9,124 (2.8%)
Education$147.83 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $200,424 | 10 | 62.5% |
| Unspecified | $74,182 | 53 | 23.1% |
| Consulting Fee | $18,843 | 9 | 5.9% |
| Travel and Lodging | $15,457 | 52 | 4.8% |
| Food and Beverage | $9,124 | 209 | 2.8% |
| Honoraria | $2,500 | 1 | 0.8% |
| Education | $147.83 | 5 | 0.0% |
Payments by Type
General
$246,495
286 transactions
Research
$74,182
53 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CIPLA USA INC. | $191,808 | 7 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $36,185 | 35 | $0 (2023) |
| Optinose US, Inc. | $20,163 | 36 | $0 (2023) |
| Circassia Pharmaceuticals Inc | $17,559 | 5 | $0 (2017) |
| GENZYME CORPORATION | $13,939 | 10 | $0 (2024) |
| GlaxoSmithKline, LLC. | $8,839 | 62 | $0 (2024) |
| Merck Sharp & Dohme LLC | $6,300 | 18 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $5,527 | 39 | $0 (2024) |
| AstraZeneca UK Limited | $4,858 | 25 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $4,008 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $192,490 | 30 | CIPLA USA INC. ($191,674) |
| 2023 | $18,056 | 41 | GENZYME CORPORATION ($13,547) |
| 2022 | $6,665 | 39 | GlaxoSmithKline, LLC. ($3,294) |
| 2021 | $2,425 | 23 | Optinose US, Inc. ($2,000) |
| 2020 | $7,064 | 18 | OptiNose US, Inc. ($5,588) |
| 2019 | $21,251 | 50 | OptiNose US, Inc. ($12,551) |
| 2018 | $21,225 | 89 | Teva Pharmaceuticals USA, Inc. ($7,903) |
| 2017 | $51,501 | 49 | Teva Pharmaceuticals USA, Inc. ($27,904) |
All Payment Transactions
339 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $32.57 | General |
| Category: Immunology | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $30.89 | General |
| Category: Immunology | ||||||
| 10/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: RESPIRATORY | ||||||
| 10/14/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $34.61 | General |
| Category: Immunology | ||||||
| 10/04/2024 | CSL Behring | Haegarda (Biological) | Education | In-kind items and services | $60.73 | General |
| Category: Immunology | ||||||
| 10/04/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: Immunology | ||||||
| 09/30/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| 09/16/2024 | kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: Allergy | ||||||
| 09/11/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $142.77 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/10/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $35.79 | General |
| Category: Immunology | ||||||
| 09/09/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,878.46 | General |
| 08/13/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $55,186.65 | General |
| 08/13/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $29,677.59 | General |
| 08/09/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $34.42 | General |
| Category: Immunology | ||||||
| 07/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/28/2024 | CIPLA USA INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $54,527.07 | General |
| 06/21/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $35.62 | General |
| Category: Immunology | ||||||
| 06/12/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $28.30 | General |
| 06/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: Immunology | ||||||
| 05/14/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $36.63 | General |
| 05/14/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Immunology | ||||||
| 05/09/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: RESPIRATORY | ||||||
| 03/29/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| C38072-AS-30066 | Teva Pharmaceuticals USA, Inc. | $23,412 | 6 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $17,434 | 4 |
| A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | GENZYME CORPORATION | $13,500 | 1 |
| An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma | Teva Pharmaceuticals USA, Inc. | $7,903 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $2,500 | 1 |
| CLI-05993AB8-02 | Chiesi USA, Inc. | $2,490 | 3 |
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | SANOFI-AVENTIS U.S. LLC | $2,031 | 5 |
| ASP2b | SANOFI-AVENTIS U.S. LLC | $872.17 | 2 |
| A Phase IIb, Randomized Stratified , Double Blind Sponsor Open , Parallel Group, Placebo Controlled, Dose Finding Study of Nemiralisib GSK2269557 Added to Standard of Care SoC Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Seve | GlaxoSmithKline, LLC. | $821.34 | 7 |
| 201832 A Randomised, Double Blind, Double Dummy, Crossover Comparison of Fluticasone Furoate Vilanterol 100 25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult Subjects with Asthma and Exercise Induced Bronchoconst | GlaxoSmithKline, LLC. | $792.20 | 1 |
| A PHASE III, 52 WEEK, RANDOMIZED, DOUBLE BLIND, 3-ARM PARALLEL GROUP S | GlaxoSmithKline, LLC. | $539.63 | 6 |
| A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MCG INHALATION POWDER (CIPLA LTD., INDIA) WITH ADVAIR DISKUS 100/50 MCG (GLAXOSMITHKLINE, USA) IN ASTHMA PATIENTS. | CIPLA USA INC. | $133.33 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma | GENZYME CORPORATION | $110.81 | 1 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $80.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 307 | 3,849 | $83,591 | $47,862 |
| 2022 | 9 | 312 | 3,072 | $73,682 | $41,127 |
| 2021 | 10 | 327 | 3,909 | $85,213 | $46,814 |
| 2020 | 9 | 285 | 3,136 | $74,971 | $40,071 |
Total Patients
1,231
Total Services
13,966
Medicare Billing
$175,873
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 47 | 1,848 | $23,100 | $17,469 | 75.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 60 | 73 | $10,220 | $7,674 | 75.1% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 43 | 638 | $22,011 | $6,649 | 30.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 53 | 72 | $6,480 | $4,788 | 73.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $5,180 | $3,973 | 76.7% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 25 | 931 | $9,776 | $3,372 | 34.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 22 | 22 | $3,190 | $1,793 | 56.2% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 11 | 208 | $2,184 | $1,538 | 70.4% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 18 | 29 | $1,450 | $606.97 | 41.9% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 45 | 1,512 | $18,900 | $13,803 | 73.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 56 | $7,840 | $6,081 | 77.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 68 | 85 | $7,650 | $5,525 | 72.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 39 | 39 | $7,215 | $5,445 | 75.5% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 43 | 531 | $18,320 | $5,019 | 27.4% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 24 | 783 | $8,222 | $2,727 | 33.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 17 | 17 | $2,465 | $1,572 | 63.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 19 | 32 | $1,600 | $675.72 | 42.2% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 14 | 17 | $1,471 | $280.16 | 19.1% |
| 95165 | Preparation and provision of single or multiple antigens for allergen immunotherapy | Office | 2021 | 39 | 1,620 | $20,250 | $15,007 | 74.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 64 | 85 | $7,650 | $6,105 | 79.8% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2021 | 39 | 589 | $20,321 | $5,928 | 29.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 39 | 39 | $7,215 | $5,276 | 73.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 39 | 47 | $6,580 | $4,451 | 67.6% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 34 | 1,148 | $12,054 | $4,344 | 36.0% |
| 95024 | Injection of allergenic extracts into skin for immediate reaction analysis | Office | 2021 | 13 | 306 | $3,213 | $2,463 | 76.6% |
About Dr. Steven Weinstein, MD
Dr. Steven Weinstein, MD is a Allergy & Immunology healthcare provider based in Huntington Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518035120.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Weinstein, MD has received a total of $320,677 in payments from pharmaceutical and medical device companies, with $192,490 received in 2024. These payments were reported across 339 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($200,424).
As a Medicare-enrolled provider, Weinstein has provided services to 1,231 Medicare beneficiaries, totaling 13,966 services with total Medicare billing of $175,873. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Huntington Beach, CA
- Active Since 12/01/2006
- Last Updated 05/08/2017
- Taxonomy Code 207K00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1518035120
Products in Payments
- CinqAir (Drug) $23,412
- Xhance (Drug) $20,163
- DUPIXENT (Biological) $15,750
- Cinqair (Biological) $7,903
- MK-7264 (Drug) $4,806
- NUCALA (Biological) $4,737
- CINQAIR (Drug) $3,908
- FASENRA (Drug) $3,572
- DUPIXENT (Drug) $3,145
- ADVAIR (Drug) $2,500
- BREZTRI (Drug) $1,516
- FEVIPIPRANT (Drug) $1,079
- RESLIZUMAB (Drug) $491.96
- Hizentra (Biological) $408.64
- TEZSPIRE (Biological) $320.63
- ProAir Digihaler (Drug) $235.00
- EUCRISA (Drug) $228.84
- Haegarda (Biological) $168.43
- BREO (Drug) $163.89
- NIOX VERO DEVICE (Device) $124.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.